

Fallopian Tube Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/FC49047DFDA5EN.html>

Date: May 2024

Pages: 132

Price: US\$ 6,499.00 (Single User License)

ID: FC49047DFDA5EN

Abstracts

The 7 major fallopian tube cancer markets are expected to exhibit a CAGR of 6.96% during 2024-2034.

The fallopian tube cancer market has been comprehensively analyzed in IMARC's new report titled "Fallopian Tube Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Fallopian tube cancer refers to the development of malignant (cancerous) cells within the fallopian tubes, which are thin, muscular ducts connecting the ovaries to the uterus in the female reproductive system. The symptoms of this condition can be nonspecific and may include abdominal or pelvic pain, abnormal vaginal bleeding, a pelvic mass or lump, bloating, changes in bowel or bladder habits, chronic back pain, constipation, indigestion, unexplained weight loss, etc. Individuals suffering from the ailment may also experience a feeling of fullness, irregular menstrual flow, white, clear, or pink discharge from the vagina, frequent urination, painful intercourse, etc. The diagnosis of fallopian tube cancer typically involves a combination of medical history evaluation, physical examination, imaging tests, and confirmatory procedures. A healthcare provider will perform a pelvic exam to check for any abnormalities or masses in the reproductive organs. Numerous other diagnostic tests, such as magnetic resonance imaging (MRI), computed tomography (CT) scans, ultrasounds, etc., are also used to visualize detailed pictures of the pelvic area and evaluate the extent of the disease among patients.

The rising prevalence of genetic predisposition resulting from specific gene mutations, which are mainly inherited from a parent, is primarily driving the fallopian tube cancer market. In addition to this, the increasing incidences of various risk factors, including early or late onset of menstruation, infertility, advancing age, family history, etc., are

also bolstering the market growth. Moreover, the widespread adoption of poly ADP ribose polymerase inhibitors, such as olaparib and niraparib, to help in repairing damaged DNA within cells is acting as another significant growth-inducing factor. Apart from this, the inflating application of the paracentesis technique, which is used to drain excess fluid in the abdomen and provide symptom relief, including decreased abdominal distension and reduced pressure on surrounding organs, is further propelling the market growth. Additionally, the escalating demand for bilateral salpingo-oophorectomy that involves the complete removal of cancerous tissue and potentially lowers the risk of recurrent disease conditions is creating a positive outlook for the market. Furthermore, the emerging popularity of targeted therapies for treating the ailment, since they work by precisely aiming at specific molecules or pathways involved in tumor growth, is expected to drive the fallopian tube cancer market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the fallopian tube cancer market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for fallopian tube cancer and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the fallopian tube cancer market in any manner.

Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

Countries Covered

United States

Germany

France

United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the fallopian tube cancer market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the fallopian tube cancer market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current fallopian tube cancer marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:
Market Insights

How has the fallopian tube cancer market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the fallopian tube cancer market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the fallopian tube cancer market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of fallopian tube cancer across the seven major markets?

What is the number of prevalent cases (2018-2034) of fallopian tube cancer by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of fallopian tube cancer by gender across the seven major markets?

How many patients are diagnosed (2018-2034) with fallopian tube cancer across the seven major markets?

What is the size of the fallopian tube cancer patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of fallopian tube cancer?

What will be the growth rate of patients across the seven major markets?

Fallopian Tube Cancer: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for fallopian tube cancer drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the fallopian tube cancer market?

What are the key regulatory events related to the fallopian tube cancer market?

What is the structure of clinical trial landscape by status related to the fallopian tube cancer market?

What is the structure of clinical trial landscape by phase related to the fallopian tube cancer market?

What is the structure of clinical trial landscape by route of administration related to the fallopian tube cancer market?

Contents

1 PREFACE

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 FALLOPIAN TUBE CANCER - INTRODUCTION

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

5 FALLOPIAN TUBE CANCER - DISEASE OVERVIEW

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

6 PATIENT JOURNEY

7 FALLOPIAN TUBE CANCER - EPIDEMIOLOGY AND PATIENT POPULATION

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
 - 7.2.1 Epidemiology Scenario (2018-2023)
 - 7.2.2 Epidemiology Forecast (2024-2034)
 - 7.2.3 Epidemiology by Age (?2018-2034?)
 - 7.2.4 Epidemiology by Gender (?2018-2034?)
 - 7.2.5 Diagnosed Cases (?2018-2034?)
 - 7.2.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.3 Epidemiology Scenario - United States
 - 7.3.1 Epidemiology Scenario (2018-2023)
 - 7.3.2 Epidemiology Forecast (2024-2034)
 - 7.3.3 Epidemiology by Age (?2018-2034?)
 - 7.3.4 Epidemiology by Gender (?2018-2034?)
 - 7.3.5 Diagnosed Cases (?2018-2034?)
 - 7.3.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.4 Epidemiology Scenario - Germany
 - 7.4.1 Epidemiology Scenario (2018-2023)
 - 7.4.2 Epidemiology Forecast (2024-2034)
 - 7.4.3 Epidemiology by Age (?2018-2034?)
 - 7.4.4 Epidemiology by Gender (?2018-2034?)
 - 7.4.5 Diagnosed Cases (?2018-2034?)
 - 7.4.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.5 Epidemiology Scenario - France
 - 7.5.1 Epidemiology Scenario (2018-2023)
 - 7.5.2 Epidemiology Forecast (2024-2034)
 - 7.5.3 Epidemiology by Age (?2018-2034?)
 - 7.5.4 Epidemiology by Gender (?2018-2034?)
 - 7.5.5 Diagnosed Cases (?2018-2034?)
 - 7.5.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.6 Epidemiology Scenario - United Kingdom
 - 7.6.1 Epidemiology Scenario (2018-2023)
 - 7.6.2 Epidemiology Forecast (2024-2034)
 - 7.6.3 Epidemiology by Age (?2018-2034?)
 - 7.6.4 Epidemiology by Gender (?2018-2034?)
 - 7.6.5 Diagnosed Cases (?2018-2034?)
 - 7.6.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.7 Epidemiology Scenario - Italy
 - 7.7.1 Epidemiology Scenario (2018-2023)
 - 7.7.2 Epidemiology Forecast (2024-2034)
 - 7.7.3 Epidemiology by Age (?2018-2034?)

- 7.7.4 Epidemiology by Gender (?2018-2034?)
- 7.7.5 Diagnosed Cases (?2018-2034?)
- 7.7.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.8 Epidemiology Scenario - Spain
 - 7.8.1 Epidemiology Scenario (2018-2023)
 - 7.8.2 Epidemiology Forecast (2024-2034)
 - 7.8.3 Epidemiology by Age (?2018-2034?)
 - 7.8.4 Epidemiology by Gender (?2018-2034?)
 - 7.8.5 Diagnosed Cases (?2018-2034?)
 - 7.8.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.9 Epidemiology Scenario - Japan
 - 7.9.1 Epidemiology Scenario (2018-2023)
 - 7.9.2 Epidemiology Forecast (2024-2034)
 - 7.9.3 Epidemiology by Age (?2018-2034?)
 - 7.9.4 Epidemiology by Gender (?2018-2034?)
 - 7.9.5 Diagnosed Cases (?2018-2034?)
 - 7.9.6 Patient Pool/Treated Cases (?2018-2034?)

8 FALLOPIAN TUBE CANCER - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

9 FALLOPIAN TUBE CANCER - UNMET NEEDS

10 FALLOPIAN TUBE CANCER - KEY ENDPOINTS OF TREATMENT

11 FALLOPIAN TUBE CANCER - MARKETED PRODUCTS

- 11.1 List of Fallopian Tube Cancer Marketed Drugs Across the Top 7 Markets
 - 11.1.1 Lynparza (Olaparib) - AstraZeneca
 - 11.1.1.1 Drug Overview
 - 11.1.1.2 Mechanism of Action
 - 11.1.1.3 Regulatory Status
 - 11.1.1.4 Clinical Trial Results
 - 11.1.1.5 Sales Across Major Markets
 - 11.1.2 Rubraca (Rucaparib) - Clovis Oncology
 - 11.1.2.1 Drug Overview

- 11.1.2.2 Mechanism of Action
- 11.1.2.3 Regulatory Status
- 11.1.2.4 Clinical Trial Results
- 11.1.2.5 Sales Across Major Markets
- 11.1.3 Zejula (Niraparib) - Janssen/Merck/GlaxoSmithKline
 - 11.1.3.1 Drug Overview
 - 11.1.3.2 Mechanism of Action
 - 11.1.3.3 Regulatory Status
 - 11.1.3.4 Clinical Trial Results
 - 11.1.3.5 Sales Across Major Markets
- 11.1.4 Avastin (Bevacizumab) - Genentech/Roche
 - 11.1.4.1 Drug Overview
 - 11.1.4.2 Mechanism of Action
 - 11.1.4.3 Regulatory Status
 - 11.1.4.4 Clinical Trial Results
 - 11.1.4.5 Sales Across Major Markets
- 11.1.5 Elahere (Mirvetuximab soravtansine) - ImmunoGen
 - 11.1.5.1 Drug Overview
 - 11.1.5.2 Mechanism of Action
 - 11.1.5.3 Regulatory Status
 - 11.1.5.4 Clinical Trial Results
 - 11.1.5.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 FALLOPIAN TUBE CANCER - PIPELINE DRUGS

- 12.1 List of Fallopian Tube Cancer Pipeline Drugs Across the Top 7 Markets
 - 12.1.1 Nemvaleukin - Alkermes plc
 - 12.1.1.1 Drug Overview
 - 12.1.1.2 Mechanism of Action
 - 12.1.1.3 Clinical Trial Results
 - 12.1.1.4 Safety and Efficacy
 - 12.1.1.5 Regulatory Status
 - 12.1.2 Oregovomab - OncoQuest
 - 12.1.2.1 Drug Overview
 - 12.1.2.2 Mechanism of Action
 - 12.1.2.3 Clinical Trial Results
 - 12.1.2.4 Safety and Efficacy

- 12.1.2.5 Regulatory Status
- 12.1.3 AVOVA1 - AiVita Biomedical
 - 12.1.3.1 Drug Overview
 - 12.1.3.2 Mechanism of Action
 - 12.1.3.3 Clinical Trial Results
 - 12.1.3.4 Safety and Efficacy
 - 12.1.3.5 Regulatory Status
- 12.1.4 ATX-101 - APIM Therapeutics
 - 12.1.4.1 Drug Overview
 - 12.1.4.2 Mechanism of Action
 - 12.1.4.3 Clinical Trial Results
 - 12.1.4.4 Safety and Efficacy
 - 12.1.4.5 Regulatory Status
- 12.1.5 Pembrolizumab - Merck & Co
 - 12.1.5.1 Drug Overview
 - 12.1.5.2 Mechanism of Action
 - 12.1.5.3 Clinical Trial Results
 - 12.1.5.4 Safety and Efficacy
 - 12.1.5.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. FALLOPIAN TUBE CANCER - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS

14. FALLOPIAN TUBE CANCER – CLINICAL TRIAL LANDSCAPE

- 14.1 Drugs by Status
- 14.2 Drugs by Phase
- 14.3 Drugs by Route of Administration
- 14.4 Key Regulatory Events

15 FALLOPIAN TUBE CANCER - MARKET SCENARIO

- 15.1 Market Scenario - Key Insights
- 15.2 Market Scenario - Top 7 Markets
 - 15.2.1 Fallopian Tube Cancer - Market Size
 - 15.2.1.1 Market Size (2018-2023)
 - 15.2.1.2 Market Forecast (2024-2034)

- 15.2.2 Fallopian Tube Cancer - Market Size by Therapies
 - 15.2.2.1 Market Size by Therapies (2018-2023)
 - 15.2.2.2 Market Forecast by Therapies (2024-2034)
- 15.3 Market Scenario - United States
 - 15.3.1 Fallopian Tube Cancer - Market Size
 - 15.3.1.1 Market Size (2018-2023)
 - 15.3.1.2 Market Forecast (2024-2034)
 - 15.3.2 Fallopian Tube Cancer - Market Size by Therapies
 - 15.3.2.1 Market Size by Therapies (2018-2023)
 - 15.3.2.2 Market Forecast by Therapies (2024-2034)
 - 15.3.3 Fallopian Tube Cancer - Access and Reimbursement Overview
- 15.4 Market Scenario - Germany
 - 15.4.1 Fallopian Tube Cancer - Market Size
 - 15.4.1.1 Market Size (2018-2023)
 - 15.4.1.2 Market Forecast (2024-2034)
 - 15.4.2 Fallopian Tube Cancer - Market Size by Therapies
 - 15.4.2.1 Market Size by Therapies (2018-2023)
 - 15.4.2.2 Market Forecast by Therapies (2024-2034)
 - 15.4.3 Fallopian Tube Cancer - Access and Reimbursement Overview
- 15.5 Market Scenario - France
 - 15.5.1 Fallopian Tube Cancer - Market Size
 - 15.5.1.1 Market Size (2018-2023)
 - 15.5.1.2 Market Forecast (2024-2034)
 - 15.5.2 Fallopian Tube Cancer - Market Size by Therapies
 - 15.5.2.1 Market Size by Therapies (2018-2023)
 - 15.5.2.2 Market Forecast by Therapies (2024-2034)
 - 15.5.3 Fallopian Tube Cancer - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
 - 15.6.1 Fallopian Tube Cancer - Market Size
 - 15.6.1.1 Market Size (2018-2023)
 - 15.6.1.2 Market Forecast (2024-2034)
 - 15.6.2 Fallopian Tube Cancer - Market Size by Therapies
 - 15.6.2.1 Market Size by Therapies (2018-2023)
 - 15.6.2.2 Market Forecast by Therapies (2024-2034)
 - 15.6.3 Fallopian Tube Cancer - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
 - 15.7.1 Fallopian Tube Cancer - Market Size
 - 15.7.1.1 Market Size (2018-2023)
 - 15.7.1.2 Market Forecast (2024-2034)

- 15.7.2 Fallopian Tube Cancer - Market Size by Therapies
 - 15.7.2.1 Market Size by Therapies (2018-2023)
 - 15.7.2.2 Market Forecast by Therapies (2024-2034)
- 15.7.3 Fallopian Tube Cancer - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
 - 15.8.1 Fallopian Tube Cancer - Market Size
 - 15.8.1.1 Market Size (2018-2023)
 - 15.8.1.2 Market Forecast (2024-2034)
 - 15.8.2 Fallopian Tube Cancer - Market Size by Therapies
 - 15.8.2.1 Market Size by Therapies (2018-2023)
 - 15.8.2.2 Market Forecast by Therapies (2024-2034)
 - 15.8.3 Fallopian Tube Cancer - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
 - 15.9.1 Fallopian Tube Cancer - Market Size
 - 15.9.1.1 Market Size (2018-2023)
 - 15.9.1.2 Market Forecast (2024-2034)
 - 15.9.2 Fallopian Tube Cancer - Market Size by Therapies
 - 15.9.2.1 Market Size by Therapies (2018-2023)
 - 15.9.2.2 Market Forecast by Therapies (2024-2034)
 - 15.9.3 Fallopian Tube Cancer - Access and Reimbursement Overview

16 FALLOPIAN TUBE CANCER - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS

17 FALLOPIAN TUBE CANCER MARKET - SWOT ANALYSIS

- 17.1 Strengths
- 17.2 Weaknesses
- 17.3 Opportunities
- 17.4 Threats

18 FALLOPIAN TUBE CANCER MARKET – STRATEGIC RECOMMENDATIONS

19 APPENDIX

I would like to order

Product name: Fallopian Tube Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/FC49047DFDA5EN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/FC49047DFDA5EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

